Year: 2024
Type: editorial
Abstract: Expert feedbackThe key starting point for obtaining regulatory uptake of an OoCbased method is a clear definition of its intended context of use (CoU).Only when the CoU is fully described and understood, does it make sense to start pursuing qualification in a meaningful way.Most OoC models have been developed for biomedical research purposes rather than regulatory applications, thus developers and end-users have to adapt these models and figure out how to use them to address regulatory information requirements.As an example, the same liver OoC model could in principle be used in a preclinical setting to evaluate the metabolic biotransformation of a new drug candidate, its pharmacological efficacy, or its potential to induce liver injury.These represent three general but distinct CoUs, which address different questions that a regulator may have.More refined descriptions of CoU also specify aspects such as therapeutic target group, population variability, and anticipated off-target pharmacology.In addition, CoU includes an indication of what other information sources are used in conjunction with the OoC-derived information, and in that frame, how the OoC results can be interpreted to arrive at a conclusion.In the preclinical assessment of new drug candidates, the context in which efficacy is assessed differs significantly with respect to the assessment of safety.Within the former, the pharmacological effect is already known and thus only therapeutically targeted organs need to be considered.For the latter however, potential off-target effects in non-target organs have to be accounted for, which typically makes it more challenging to employ a single OoC for safety assessment.When devising qualification strategies for OoC methods used in efficacy or safety studies, the relevant exposure scenario has to be considered, including the nominal dose, the route of exposure (e.g., dermal, inhalation or oral), and whether the drug is administered once or repeatedly over a period of time.For efficacy assessment, the comparative standard is usually the treatment applied in clinical practice, thus in-vivo-to-in-vitro extrapolation and related allometric-type scaling are required to ensure an equivalent internal dosing scenario within the OoC model.A satisfactory level of qualification can only be achieved with a sufficient level of standardization, and vice versa.Thus, the development of OoC qualification frameworks and associated criteria should both reflect and influence ongoing efforts to address standardization of OoC (Piergiovanni et al., 2021a,b).Standards
Source: ALTEX
Institution: Joint Research Centre
Language: English
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W4392251231
